Nephrocare Health Services IPO Subscription Day 1

Here, the Nephrocare Health Services IPO launched on 10th December 2025. Bidding for the issue will close today, 12th December 2025. The primary aim of the Nephrocare Health Services IPO is to raise ₹871.05 crores from the market. Also, the = IPO has received an impressive level of subscription, indicating that the shares will be listed at an impeccable premium. Scroll down to check the Nephrocare Health Services IPO subscription and details. 

Nephrocare Health Services IPO Details 

The price band for Riddhi Display Equipment’s IPO has been set at ₹438 to ₹460 per share, and a total of 1,89,35,819 shares are being issued. Let’s segregate the share quota fixed for different categories of investors. 

Nephrocare Health Services IPO Subscription Status

As of now, the Nephrocare Health Services IPO has been subscribed to 0.12 times. Of these, 0.20 times are subscribed by retail investors, 0.09 times by non-institutional investors, and 0.00 times by QII (Qualified Institutional Investors).  

The healthy subscription status indicates that investors are expecting higher returns at the time of Nephrocare Health Services’s IPO listing on 17th December 2025. Nephrocare Health Services also has a positive outlook behind the fresh issue of 0.77 crore shares, which will raise around Rs 871.05 crores.

Nephrocare Health Services IPO GMP Today

We know that higher subscription levels drive grey-market premiums for IPOs. Let’s explore the Nephrocare Health Services IPO GMP for 10th December 2025. 

The grey market premium for this IPO has surged to 0.00% or Rs 0 per share. It indicates that the estimated listing price per share is Rs 460.00. Numerous factors played a pivotal role in this jump in the GMP of Riddhi Display Equipment’s IPO. These include higher subscription rates, favourable market sentiment, and investors’ positive attitude towards IPOs. 

About Nephrocare Health Services Ltd.

Nephrocare Health Services was established in 2010. Nephrocare Health Services Ltd. provides end-to-end dialysis care through a vast network of clinics across India and select international markets. The company offers services including diagnosis, haemodialysis, home and mobile dialysis, and wellness programs, supported by an in-house pharmacy. As of Sep 30, 2025, Nephrocare operated 519 clinics with 51 across the Philippines, Uzbekistan, and Nepal. This includes the world’s largest dialysis clinic in Uzbekistan. In India, the company had a presence across 288 cities in 21 States and 4 Union Territories. Approximately 77.53% of its clinics were located in tier II and tier III cities, addressing a critical need in underserved regions. During Fiscal 2025, Nephrocare served 29,281 patients and completed 2,885,450 dialysis treatments, accounting for roughly 10% of the country’s total dialysis patient base. Additionally, by Sep 30, it has served 31,046 patients and completed 1,591,377 treatments in India. As of Sep 30, 2025, the company has 5,562 dialysis machines.

Nephrocare Health Services Limited Financials

The company’s financial analysis is essential before applying for the Nephrocare Health Services IPO. Look at the table to learn about Nephrocare Health Services Limited’s financials. 

Explanation

Nephrocare Health Services Limited’s revenue increased by 34% from ₹574.72 crores in March 2024  to ₹769.92 crores in March 2025. Moreover, the company’s PAT increased by 91% from ₹35.13 crores in March 2024 to ₹67.10 crores in March 2025.

Technical Indicators

Several technical indicators are available to assess a company’s potential to deliver returns. Use the parameters mentioned below to analyse the technical aspects of the Nephrocare Health Services IPO.

Nephrocare Health Services IPO Listing Expectations

Nephrocare Health Services IPO Highlights: IPO allotment is still pending, as the bid will close today. However, given the current GMP or market sentiment, it is reasonable to expect higher listing gains for the share. A jump of 0.00% in Yash Highlight GMP suggests the estimated listing price per share will be around Rs 460.

It will provide higher listing gains to investors who applied for this IPO. Also, the financial fundamentals of this business made it the experts’ top long-term recommendation. 

Nephrocare Health Services IPO Dates

Note: IPO GMP is volatile and depends on market sentiment. Hence, one should conduct research before investing.

Recent Articles

Icodex Publishing Solutions IPO GMP: Day 1 IPO Live Updates

Bluestone Jewellery IPO GMP: Day 1 IPO Live Updates

Highway Infrastructure IPO Listing Preview: What to Expect Now in 2025?

Concord Biotech Q1 Results FY26: Q1 PAT Falls 26.07% to ₹44.06 Crore; Revenue Down 5.47% YoY

Action Construction Equipment Q1 Results FY26: Q1 PAT Rises 16.08% to ₹97.72 Crore; Revenue Down 11.19% YoY

Sawaliya Foods Products IPO Allotment Status Check Online: GMP, Subscription, Price, and More

Nephrocare Health Services IPO Allotment Status Check Online: GMP, Subscription, Price, and More

Mahendra Realtors IPO GMP & Review: Apply or Avoid?

Regaal Resources IPO GMP & Review: Apply or Avoid?

Icodex Publishing Solutions IPO GMP & Review: Apply or Avoid?